Physician profile
Wayne Davis
NPI 1215165741
$6,170.56
in general payments reported to CMS, 2019-2025
41 companies · $878 in 2025
The $878 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $157 · 2020: $162 · 2021: $888 · 2022: $1,083 · 2023: $1,506 · 2024: $1,497 · 2025: $878.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,881.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,880.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,074.74 | 2019-2025 | Ozempic, Rybelsus, Tresiba |
| Abbvie INC. | $970.01 | 2021-2025 | Vraylar, Dalvance, Teflaro |
| Amgen INC. | $515.12 | 2019-2025 | Repatha, Otezla, Krystexxa |
| Lilly USA, LLC | $465.66 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $271.83 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Astellas Pharma US INC | $255.01 | 2023-2025 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $239.01 | 2019-2024 | Xifaxan |
| Pfizer INC. | $197.44 | 2022-2024 | |
| Janssen Pharmaceuticals, INC | $190.13 | 2021-2022 | |
| Abiomed | $175.36 | 2024-2025 | Impella |
| Dexcom, INC. | $173.51 | 2023-2025 | Dexcom G6 Transmitter |
| Antares Pharma, INC. | $161.84 | 2021-2024 | Xyosted, Nocdurna, Tlando |
| Medtronic, INC. | $146.50 | 2023 | O-Arm |
| Anika Therapeutics, INC. | $135.63 | 2024 | Integrity |
| Esperion Therapeutics, INC. | $130.06 | 2021-2023 | Nexletol |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $114.74 | 2023-2024 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $94.04 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $80.37 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $72.72 | 2023-2025 | |
| Astrazeneca Pharmaceuticals Lp | $71.81 | 2020-2025 | Farxiga, Airsupra |
| Corium, LLC | $67.05 | 2022-2023 | Azstarys |
| Glaxosmithkline, LLC. | $66.90 | 2023-2025 | Shingrix, Arexvy |
| Genentech USA, INC. | $50.85 | 2019-2022 | |
| Verity Pharmaceuticals INC. | $49.72 | 2025 | Tlando |
| Eyevance Pharmaceuticals LLC | $48.23 | 2021 | |
| Hikma Pharmaceuticals USA | $48.23 | 2021 | |
| Halozyme INC | $46.37 | 2023 | |
| Boston Scientific Corporation | $27.47 | 2025 | Bodyguardian |
| Takeda Pharmaceuticals U.S.A., INC. | $26.79 | 2021-2022 | |
| Eisai INC. | $25.92 | 2025 | |
| Lundbeck LLC | $22.48 | 2025 | Rexulti |
| Globus Medical, INC. | $20.90 | 2025 | Senza |
| Merck Sharp & Dohme LLC | $18.11 | 2024 | Gardasil, Capvaxive, Gardasil 9 |
| Edwards Lifesciences Corporation | $17.80 | 2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Tolmar, INC. | $16.07 | 2024 | |
| Inspire Medical Systems, INC. | $15.79 | 2025 | Inspire |
| Currax Pharmaceuticals LLC | $15.48 | 2023 | Contrave |
| Inari Medical, INC. | $13.51 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Gt Medical Technologies, INC | $13.03 | 2022 | |
| Allergan, INC. | $12.62 | 2020 | |
| Phathom Pharmaceuticals, INC. | $11.71 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wayne Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.